Evidence map›Paper›PMID 29675798›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2018

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.

Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Comparative effectiveness of semaglutideFrontiers in pharmacology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Levels of evidence supporting European and American community-acquired pneumonia guidelines.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Article
  15. Article
  16. Oral GLP1 Analog: Where Does the Tide Go?Clinical medicine insights. Endocrinology and diabetes · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Michal WitkowskiDRG Abacus, Bicester, Oxfordshire, UK.
Lars WilkinsonNovo Nordisk A/S, Søborg, Denmark.
Neil WebbDRG Abacus, Bicester, Oxfordshire, UK. nwebb@teamdrg.com.
Alan WeidsDRG Abacus, Bicester, Oxfordshire, UK.
Divina GlahNovo Nordisk Ltd, Gatwick, UK.
Hrvoje VrazicNovo Nordisk A/S, Søborg, Denmark.ORCID http://orcid.org/0000-0001-8151-9899
Novo Nordisk (Denmark) · DKNovo Nordisk (United Kingdom) · GBOxfordshire Clinical Commissioning Group · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOnce-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1-2 oral anti-diabetic drugs (OADs) vs other GLP-1 receptor agonists (GLP-1 RAs) are limited, a network meta-analysis (NMA) was performed. The objective was to assess the relative efficacy and safety of once-weekly semaglutide vs GLP-1 RAs in patients with type 2 diabetes (T2D) inadequately controlled on 1-2 OADs.

methodsA systematic literature review (SLR) was conducted in order to identify trials of GLP-1 RAs in patients inadequately controlled on 1-2 OADs. Data at 24 ± 4 weeks were extracted for efficacy and safety outcomes (feasible for analysis in a NMA), which included the key outcomes of change from baseline in glycated hemoglobin (HbA

resultsIn total, 26 studies were included across the base case analyses. Once-weekly semaglutide 1.0 mg was associated with significantly greater reductions in HbA

conclusionOverall, once-weekly semaglutide 1.0 mg as an add-on to 1-2 OADs is the most efficacious GLP-1 RA in terms of the reduction of HbA

fundingNovo Nordisk.

Indexed as

GLP-1 receptor agonistGlycemic controlHbA1cNetwork meta-analysisSemaglutideSystematic reviewSystolic blood pressureType 2 diabetesWeight

Identifiers

PMID29675798
PMCPMC5984927
OpenAlexW2802523429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.